Livin modulates the apoptotic effects of vesicular stomatotitis virus in lung adenocarcinoma

Liu,Gui-Hong; Wang,Wei-Lin; Wang,Chun; Li,Chang-Lin; Zhang,Xiao-Long; Li,Qiu; Ding,Zhen-Yu

doi:10.3892/ijo.2015.3183

Livin modulates the apoptotic effects of vesicular stomatotitis virus in lung adenocarcinoma

Authors:
- Gui-Hong Liu
- Wei-Lin Wang
- Chun Wang
- Chang-Lin Li
- Xiao-Long Zhang
- Qiu Li
- Zhen-Yu Ding
View Affiliations

Affiliations: Division of Thoracic Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, P.R. China, Department of Oncology, Chengdu First People's Hospital, Chengdu 610041, P.R. China, Division of Endocrinology and Metabolism, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, P.R. China, Division of Abdominal Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, P.R. China
Published online on: September 24, 2015 https://doi.org/10.3892/ijo.2015.3183
Pages: 1775-1782

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vesicular stomatitis virus (VSV) has shown promise in cancer treatment. However, it achieved limited effects against lung cancer. Lung cancer has intrinsic mechanisms that render resistance to VSV. In this study, we attempted to explore the expression of the anti-apoptotic factor Livin in lung adenocarcinoma and its possible relationship to VSV vulnerability. We found VSV induced apoptosis in a time- and dose-dependent manner, with the concomitant change in the expression of Livin. We elevated the expression of Livin both transiently and stably, and the cells became insensitive to VSV treatment. We further found the BIR domain of Livin was mainly responsible for its modulation effects. This finding suggested a possible interaction with the second mitochondria-derived activator of caspase (SMAC). The knock-down of SMAC also inhibited apoptosis by VSV. The relationship was confirmed by the co-immunoprecipitation. Finally, we knocked down the endogenous Livin, and the knock-down sensitized cells to VSV treatment. Our results suggested the important role of Livin and its partner molecule in the process of VSV treatment.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
2	Reck M, Heigener DF, Mok T, Soria JC and Rabe KF: Management of non-small-cell lung cancer: Recent developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
3	Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N and Bell JC: Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 6:821–825. 2000. View Article : Google Scholar : PubMed/NCBI
4	Balachandran S, Porosnicu M and Barber GN: Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol. 75:3474–3479. 2001. View Article : Google Scholar : PubMed/NCBI
5	Ebert O, Shinozaki K, Huang TG, Savontaus MJ, García-Sastre A and Woo SL: Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res. 63:3605–3611. 2003.PubMed/NCBI
6	Li Q, Wei YQ, Wen YJ, Zhao X, Tian L, Yang L, Mao YQ, Kan B, Wu Y, Ding ZY, et al: Induction of apoptosis and tumor regression by vesicular stomatitis virus in the presence of gemcitabine in lung cancer. Int J Cancer. 112:143–149. 2004. View Article : Google Scholar : PubMed/NCBI
7	Lin X, Chen X, Wei Y, Zhao J, Fan L, Wen Y, Wu H and Zhao X: Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice. Gynecol Oncol. 104:540–546. 2007. View Article : Google Scholar
8	Du XB, Lang JY, Xu JR, Lu Y, Wen YJ, Zhao JM, Diao P, Yuan ZP, Yao B, Fan LY, et al: Vesicular stomatitis virus matrix protein gene enhances the antitumor effects of radiation via induction of apoptosis. Apoptosis. 13:1205–1214. 2008. View Article : Google Scholar : PubMed/NCBI
9	Stewart JH IV, Ahmed M, Northrup SA, Willingham M and Lyles DS: Vesicular stomatitis virus as a treatment for colorectal cancer. Cancer Gene Ther. 18:837–849. 2011. View Article : Google Scholar : PubMed/NCBI
10	Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND, Edmondson S, Devenish RJ and Ralph SJ: Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem. 272:28779–28785. 1997. View Article : Google Scholar : PubMed/NCBI
11	Moussavi M, Fazli L, Tearle H, Guo Y, Cox M, Bell J, Ong C, Jia W and Rennie PS: Oncolysis of prostate cancers induced by vesicular stomatitis virus in PTEN knockout mice. Cancer Res. 70:1367–1376. 2010. View Article : Google Scholar : PubMed/NCBI
12	Gyrd-Hansen M and Meier P: IAPs: From caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer. 10:561–574. 2010. View Article : Google Scholar : PubMed/NCBI
13	Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS and Dixit VM: ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol. 10:1359–1366. 2000. View Article : Google Scholar : PubMed/NCBI
14	Lin JH, Deng G, Huang Q and Morser J: KIAP, a novel member of the inhibitor of apoptosis protein family. Biochem Biophys Res Commun. 279:820–831. 2000. View Article : Google Scholar
15	Ashhab Y, Alian A, Polliack A, Panet A and Ben Yehuda D: Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett. 495:56–60. 2001. View Article : Google Scholar : PubMed/NCBI
16	Tanabe H, Yagihashi A, Tsuji N, Shijubo Y, Abe S and Watanabe N: Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer. Lung Cancer. 46:299–304. 2004. View Article : Google Scholar : PubMed/NCBI
17	Gazzaniga P, Gradilone A, Giuliani L, Gandini O, Silvestri I, Nofroni I, Saccani G, Frati L and Aglianò AM: Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol. 14:85–90. 2003. View Article : Google Scholar
18	Choi J, Hwang YK, Sung KW, Lee SH, Yoo KH, Jung HL, Koo HH, Kim HJ, Kang HJ, Shin HY, et al: Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood. 109:471–477. 2007. View Article : Google Scholar
19	Xiang Y, Yao H, Wang S, Hong M, He J, Cao S, Min H, Song E and Guo X: Prognostic value of Survivin and Livin in nasopharyngeal carcinoma. Laryngoscope. 116:126–130. 2006. View Article : Google Scholar : PubMed/NCBI
20	Gong J, Chen N, Zhou Q, Yang B, Wang Y and Wang X: Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus, but similarly in primary and metastatic melanomas. J Clin Pathol. 58:1081–1085. 2005. View Article : Google Scholar : PubMed/NCBI
21	Ding ZY, Liu GH, Olsson B and Sun XF: Upregulation of the antiapoptotic factor Livin contributes to cisplatin resistance in colon cancer cells. Tumour Biol. 34:683–693. 2013. View Article : Google Scholar
22	Liu GH, Wang C and Ding ZY: Overexpression of the truncated form of Livin reveals a complex interaction with caspase-3. Int J Oncol. 42:2037–2045. 2013.PubMed/NCBI
23	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
24	Luo J, Solimini NL and Elledge SJ: Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell. 136:823–837. 2009. View Article : Google Scholar : PubMed/NCBI
25	Kopecky SA and Lyles DS: Contrasting effects of matrix protein on apoptosis in HeLa and BHK cells infected with vesicular stomatitis virus are due to inhibition of host gene expression. J Virol. 77:4658–4669. 2003. View Article : Google Scholar : PubMed/NCBI
26	Gadaleta P, Perfetti X, Mersich S and Coulombié F: Early activation of the mitochondrial apoptotic pathway in Vesicular Stomatitis virus-infected cells. Virus Res. 109:65–69. 2005. View Article : Google Scholar : PubMed/NCBI
27	Gaddy DF and Lyles DS: Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx. J Virol. 81:2792–2804. 2007. View Article : Google Scholar :
28	Tumilasci VF, Olière S, Nguyên TL, Shamy A, Bell J and Hiscott J: Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis. J Virol. 82:8487–8499. 2008. View Article : Google Scholar : PubMed/NCBI
29	Igney FH and Krammer PH: Death and anti-death: Tumour resistance to apoptosis. Nat Rev Cancer. 2:277–288. 2002. View Article : Google Scholar : PubMed/NCBI
30	Schache P, Gürlevik E, Strüver N, Woller N, Malek N, Zender L, Manns M, Wirth T, Kühnel F and Kubicka S: VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1. Gene Ther. 16:849–861. 2009. View Article : Google Scholar : PubMed/NCBI
31	Vucic D, Franklin MC, Wallweber HJ, Das K, Eckelman BP, Shin H, Elliott LO, Kadkhodayan S, Deshayes K, Salvesen GS, et al: Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: Implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem J. 385:11–20. 2005. View Article : Google Scholar :
32	Wu H, Tschopp J and Lin SC: Smac mimetics and TNFalpha: A dangerous liaison? Cell. 131:655–658. 2007. View Article : Google Scholar : PubMed/NCBI